Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
J Eur Acad Dermatol Venereol
; 36(10): 1796-1804, 2022 Oct.
Article
in En
| MEDLINE
| ID: mdl-35696305
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Eur Acad Dermatol Venereol
Year:
2022
Document type:
Article